NETEC Resource Library

Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus

Item

Click for External Resource*


Click to read full article*


*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.


Files for Download

Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirushttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946014/pdf/ciw256.pdf

Item Type

Publication

Terms of Use

By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.

Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.

Document Viewer

Was this resource helpful?


Title

Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus

Subject

Description

From September 2014 to April 2015, 6 persons who had occupational exposures to Zaire ebolavirus in West Africa received investigational agent rVSV-ZEBOV or TKM-100802 for postexposure prophylaxis and were monitored in the United States.

Date

2016-08-01

Citation

Wong, K. K., R. T. Davey, Jr., A. L. Hewlett, C. S. Kraft, A. K. Mehta, M. J. Mulligan, A. Beck, W. Dorman, C. J. Kratochvil, L. Lai, T. N. Palmore, S. Rogers, P. W. Smith, A. F. Suffredini, M. Wolcott, U. Stroher and T. M. Uyeki (2016). "Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus." Clin Infect Dis 63(3): 376-379.

Abstract

From September 2014 to April 2015, 6 persons who had occupational exposures to Zaire ebolavirus in West Africa received investigational agent rVSV-ZEBOV or TKM-100802 for postexposure prophylaxis and were monitored in the United States. All patients experienced self-limited symptoms after postexposure prophylaxis; none developed Ebola virus disease.

Accessibility

free online - Pubmed Central

Collection